[1]. Hamamatsu University Hospital Surgery 1 第一外科診療科群主任診療科長

1999/5/- 2001/4/30 慶應義塾大学病院
2000/5/1- 2001/4/30 大田原赤十字病院
2001/5/1- 2002/4/30 国立霞ヶ浦病院
2002/5/1- 2007/4/30 慶應義塾大学
2003/10/1- 2004/4/30 済生会宇都宮病院
2004/4/1- 2006/3/31 慶應義塾大学
2004/5/1- 2006/3/30 国立成育医療センター研究所
2004/5/1- 2005/9/ 国立成育医療センター研究所
2005/12/- 2006/3/ 国立成育医療センター研究所
2006/4/1- 2007/4/30 慶應義塾大学
2007/5/1- 2008/6/30 OLV Clinic Cardiovascular and Thoracic Surgery Clinical Fellow
2008/7/1- 2009/3/31 Policlinico San Donato Carduichirurgia Clinical Fellow
2009/4/1- 2010/3/31 慶應義塾大学
2010/1/1- 2010/9/30 Chiang Mai University Cardiothoracic Surgery Clinical Fellow
2010/10/1- 2012/3/31 慶應義塾大学
2012/4/1- 2016/10/31 慶應義塾大学
2016/11/1- 慶應義塾大学
2016/11/1- 2021/3/31 明石医療センター
2019/3/1- 公益財団法人 神戸医療産業都市推進機構
2019/4/1- 2020/3/31 神戸大学
2021/4/1- 2024/10/31 近畿大学
2024/11/1- 浜松医科大学
2025/4/1- 慶應義塾大学

1993/3/31 withdrawn before completion The University of Tokyo 教養学部 理科Ⅰ類
1999/3/31 graduated Keio University 医学部
2006/3/31 withdrawn after completion of required course credits Keio University 医学研究科

PhD. (Surgery) Keio University
Bachelor of Medicine Keio University

[1]. 1999/5/12 MD

[1]. Cardiovascular Surgery

[1]. 低侵襲心臓手術システム基盤構築

[1]. Investigation of Exercise-Induced Pressor Reflex Characteristics in Valvular Heart Disease and Evaluation of the Effects of Catheter-Based Interventions
[2]. Standardization of Cardiovascular Surgical Training through Markerless Motion Analysis Enabled by AI
[3]. Optimal Timing of Thoracic Endovascular Aortic Repair for Subacute and Chronic Type B Aortic Dissection
[4]. Development of Transplantable Grafts Using Decellularized Cardiac and Vascular Matrix with Seeded Differentiated Cells
[5]. Development of Organ Regeneration Technologies and Novel Transplantation Therapies Using Stem Cell Packaging
[6]. Study on the Safety and Efficacy of Stentless Mitral Valve Replacement Using Autologous Pericardium
[7]. Establishment of a Treatment for Severe Heart Failure Using Transplantation of iPSC-Derived Cardiomyocytes
[8]. Creation of a Transplantable Heart Using Decellularized Three-Dimensional Cardiac Scaffold and Human Fetal-Derived Mesenchymal Cells
[9]. Development of a Treatment for Severe Heart Failure Using Human Fetal Appendage-Derived Mesenchymal Cells and Cardiomyocyte-Inducing Molecules
[10]. 低侵襲・内視鏡下心臓弁膜症手術で世界をリードするための標準化・普及事業
[11]. Development of Fundamental Technologies for the Clinical Application of a Minimally Invasive Human Stem Cell Delivery System for Severe Heart Failure